Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Thamlikitkul, Visanu ^a   Dubrovskaya, Yanina ^b   Manchandani, Pooja ^c   Ngamprasertchai, Thundon ^a   Boonyasiri, Adhiratha ^a   Babic, Jessica T ^c,d   Tam, Vincent H ^c,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Dosing adjustment; Drug exposure; Polymyxins

Indexed keywords

CREATININE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; AGED; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM;

ADMINISTRATION, INTRAVENOUS; AGED; ANTI-BACTERIAL AGENTS; CREATININE; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; POLYMYXIN B; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY;

EID: 85009241638     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01337-16     Document Type: Article

References (15)

1. Cai Y, Lee W, Kwa AL. 2015. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther 13:1481-1497. https://doi.org/10.1586/14787210.2015.1093933.
2. Kassamali Z, Danziger L. 2015. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy 35:17-21. https://doi.org/10.1002/phar.1510.
3. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58:2740-2746. https://doi.org/10.1128/AAC.02476-13.
4. Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ. 2015. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother 59:7000-7006. https://doi.org/10.1128/AAC.00844-15.
5. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231-2237. https://doi.org/10.1093/jac/dkq285.
6. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. https://doi.org/10.1093/cid/cit334.
7. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. https://doi.org/10.1086/592577.
8. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624-3630. https://doi.org/10.1128/AAC.49.9.3624-3630.2005.
9. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56:5724-5727. https://doi.org/10.1128/AAC.01333-12.
10. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. 2015. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother 59:2720-2725. https://doi.org/10.1128/AAC.04110-14.
11. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. 2011. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55:5893-5899. https://doi.org/10.1128/AAC.00387-11.
12. Kwa AL, Abdelraouf K, Low JG, Tam VH. 2011. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 52:1280-1281. https://doi.org/10.1093/cid/cir137.
13. Manchandani P, Dubrovskaya Y, Gao S, Tam VH. 2016. Comparative pharmacokinetic profiling of different polymyxin B components. Antimicrob Agents Chemother. Epub ahead of print.
14. Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH. 2015. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother 59:7121-7123. https://doi.org/10.1128/AAC.01815-15.
15. He J, Gao S, Hu M, Chow DS, Tam VH. 2013. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 68:1104-1110. https://doi.org/10.1093/jac/dks536.